Neuroscience Clinical Trial Experience

The central nervous system affects physical and behavioral health in untold ways. Unraveling the field’s complexity requires an understanding that comes only from experience.

prcom_Asset 1ARROW

Breaking barriers in neuroscience

A nuanced approach to a uniquely complex field

Neurological outcomes can seldom be measured just by lab results. Having performed more than 250 studies across the field in the past five years, we have the hands-on experience and knowledgeable staff to provide the precise approach your trial needs and to anticipate and overcome the obstacles – for example, finding ways to manage screen failure rates in Alzheimer’s trials that reach as high as 70 percent.

Today is a fascinating time to work in neuroscience drug development as we help the most innovative sponsors unlock the mysteries of the central nervous system. Our neuroscience clinical research professionals leverage their background in a diverse range of psychiatric and neurological indications to ensure that we provide you with the best possible regulatory and scientific, medical, and operational delivery advice.

Why choose Premier?
  • Our work has touched more than 50,000 patients afflicted by just about every major central nervous system disorder
  • More than half of our work is in rare diseases
  • We have a history of breakthrough work, including the first post-traumatic stress disorder study in military veterans

PREMIER PERSPECTIVE

Disease-modifying therapies in Parkinson’s disease

Researchers have made many attempts at disease modification as they pursue breakthroughs in treating Parkinson’s disease, but so far without success. Why have these efforts failed, and what’s next?

PREMIER INSIGHT

Positive results delivered ahead of time

With unanticipated interest in these pivotal Phase 3 studies, Premier Research needed to line up and train the right resources while collaborating effectively with the central laboratory, data manager, and other participants.

Featured Resources

WEBINAR

WEBINAR

Pursuing Parkinson’s Disease Gene Therapies: Strategies & Operational Requirements

White Paper

White Paper

The Role of Long-Acting Injectable Antipsychotics in Schizophrenia

Premier Insight

Premier Insight

#255: Merging Science and Nuance to Treat Post-Traumatic Stress Disorder

Premier Thought Leadership

Krista Armstrong

SVP, Clinical Development Services, & Global Head of Neuroscience

Dr. Armstrong’s primary therapeutic and operational expertise has had a specific emphasis on psychiatric indications such as ADHD, schizophrenia, mood disorders, ASD, eating disorders, substance use disorders and PTSD as well as neurological conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, epilepsy and stroke.

Connect with us

Ready to get started? So are we. Drop us a line to learn more about how we can help.